ReviewClinics (Sao Paulo, Brazil)2021
Post SARS-CoV-2 vaccination Guillain-Barre syndrome in 19 patients.
Review in Clinics (Sao Paulo, Brazil), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- COVID-19 Vaccines Effectiveness and Safety in Trinidad and Tobago: A Systematic Review and Meta-Analysis.Microorganisms · 2025Review
- Article
- What Is the Impact of the Novel Coronavirus and the Vaccination on Guillain-Barre Syndrome?Molecular neurobiology · 2024Review
- Clinical and Diagnostic Features of Post-Acute COVID-19 Vaccination Syndrome (PACVS).Vaccines · 2024Article
- The Impact of COVID-19 on the Guillain-Barré Syndrome Incidence.Biomedicines · 2024Review
- Needle EMG of the vagus-innervated striated larynx muscles cannot indicate laryngeal sensory neuropathy.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2023Article
- Neurological Disorders following COVID-19 Vaccination.Vaccines · 2023Review
- Neurological sequelae of vaccines.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Review
- A review of neurological side effects of COVID-19 vaccination.European journal of medical research · 2023Review
- Guillain-Barre syndrome following COVID-19 vaccines: A review of literature.Frontiers in immunology · 2023Review
- Guillain-Barre Syndrome Following SARS-CoV-2 Vaccination: A Case Report.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2022Article
- Side effects of SARS-CoV-2 vaccines should be assessed by unbiased professionals on-site.Human vaccines & immunotherapeutics · 2022Article
- Letter to the Editor: Rule Out Alternative Mechanisms Before Attributing Elevated Hemidiaphragm to Parsonage Turner Syndrome and SARS-CoV-2 Vaccination.Journal of Korean medical science · 2022Article
- Spectrum of Neurological Complications Following COVID-19 Vaccination in India.Journal of clinical neurology (Seoul, Korea) · 2022Article
- [Guillain-Barre syndrome and thrombocytopenia after SARS-CoV-2 vaccination with Moderna. A case report].Revista de neurologia · 2022Article
- Article
- Article
- COVID-19 vaccine-related Guillain-Barré syndrome in the Liguria region of Italy: A multicenter case series.Journal of the neurological sciences · 2022Article
- Safety of COVID-19 Vaccines: Spotlight on Neurological Complications.Life (Basel, Switzerland) · 2022Review
- Post-Vaccinal Encephalitis with Early Relapse after BNT162b2 (COMIRNATY) COVID-19 Vaccine: A Case Report.Vaccines · 2022Article
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2 vaccinations are not free from side effects. Usually, they are mild or moderate but occasionally severe. One of these severe side effects is Guillain-Barré syndrome (GBS). This review summarizes and discusses GBS as a side effect of SARS-CoV-2 vaccinations (SCoVaG) based on recent research reports. Altogether, nine articles reporting 18 patients with SCoVaG were identified and one more report on another patient is under review. The age for the studies ranged between 20-86y. Nine patients were male, and ten were female. In all 19 patients, SCoVaG developed after the first dose of the vaccine. The Astra Zeneca vaccine was used in fourteen patients, the Pfizer vaccine in four patients, and the Johnson & Johnson vaccine was applied in one patient. The latency between vaccination and onset of GBS ranged from 3h to 39d. The treatment of SCoVaG included IVIGs (n=13), steroids (n=3), or no therapy (n=3). Six patients required mechanical ventilation. Only a single patient recovered completely and partial recovery was achieved in nine patients. In conclusion, GBS may develop time-linked to the first dose of a SARS-CoV-2 vaccination. Though a causal relationship between SARS-CoV-2 vaccinations and SCoVaG remains speculative, more evidence is in favour than against it.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.